The BDFA is delighted to share that Tern Therapeutics, a biotechnology company based in the USA have entered into a global licensing agreement with REGENXBIO Inc. for RGX-381 and RGX-181.
The company’s Chief Executive Officer, Alex Bailey and Chief Medical Officer, Christina Ohnsman were both instrumental to the development of the CLN2 programs in their previous roles at REGENXBIO. They will be using their experience and unique capabilities to initially focus on continuing the RGX-381 clinical trial in the UK at GOSH through to completion.
The BDFA will be working in close contact with Tern Therapeutics, also continuing to work with REGENXBIO, and we are thrilled with the news of this licensing agreement, which will bring hope to the CLN2 community.
We are pleased to share the company’s full press release, which contains a quote from Liz Brownnutt CEO of the BDFA, and a letter to the community from REGENXBIO.
Read the Tern Press Release HERE
Read Regenxbio Letter to Community HERE
Please get in touch with Liz if you have any questions – lizbrownnutt@bdfa-uk.org.uk 07745210212 See less
